Vericel Corporation has released a presentation detailing its advanced therapies in sports medicine and severe burn care markets. The company highlights its strong financial profile, with a focus on high revenue growth and sustained positive adjusted EBITDA. In sports medicine, Vericel is noted as a market leader in knee cartilage repair, with significant growth from the launch of MACI Arthro in 2024. The burn care franchise, having launched in the U.S. in late 2023, is positioned as a potentially life-saving product with a large market opportunity. Additionally, plans are in place for expanding the core portfolio, including a new manufacturing facility to potentially support MACI expansion outside the U.S. The total addressable market for Vericel's offerings is projected to grow to over $5 billion in the coming years. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.